Skip to main content
TTRX
NASDAQ Life Sciences

Turn Therapeutics Files $150M Shelf and Launches $50M TD Cowen ATM

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.48
Mkt Cap
$289.45M
52W Low
$2.57
52W High
$16.45
52W Position info
269% above low
Off High info
42% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

TTRX has more than doubled off its 52-week low of $2.57.

Summary

Turn Therapeutics registered a $150 million shelf and a $50 million at-the-market stock program with TD Cowen. No shares have been sold; the company gains a standing ability to raise cash, at the price of dilution when it draws.


Key Events · Financing and Capital Events · TTRX

  • $150M Shelf Plus $50M ATM Registered

    The S-3 registers up to $150,000,000 of common stock, preferred stock, debt securities, warrants, rights and units, alongside a $50,000,000 sales agreement prospectus for common stock sold through TD Cowen.

  • No Shares Sold Yet

    This filing registers capacity only; no proceeds reach the company until it delivers placement notices and shares are actually sold under the sales agreement.

  • Dilution Math at Current Price

    At the $9.48 last reported sale price on November 6, 2026, the full $50,000,000 ATM equals about 5,274,262 shares — roughly 17% of the 30,572,704 shares outstanding.

  • Agent Fees and Expenses

    TD Cowen receives up to 3.0% of gross proceeds plus reimbursement of up to $100,000 of its legal expenses; total offering expenses excluding commissions are estimated at about $300,000.


Analysis · TTRX · Life Sciences

The lifeline here is capacity, not cash: Turn Therapeutics can now sell up to $150 million of securities over time, including up to $50 million of common stock through TD Cowen at market prices. No shares have been sold yet, so this is a standing ability to raise, not a completed raise. For a clinical-stage biotech carrying a going-concern warning and $10.4 million of cash, that drip-feed equity option is the main funding backstop — and the cost is dilution on every drawdown. At the $9.48 last sale price, the full $50 million ATM would be roughly 5.27 million shares, or about 17% of the 30.57 million shares outstanding, and that sits on top of the 25.4 million shares registered for resale in the companion S-3 filed today.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TTRX was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.5M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TTRX - Latest Insights

TTRX
Nov 09, 2026, 8:00 AM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $9.48
Real-time Price: $9.48 info
Change: $0 (0%) info
Market Cap: $289.45M info
TTRX
Nov 09, 2026, 7:02 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $9.48 info
Change: $0 (0%) info
Market Cap: $289.45M info
TTRX
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $9.48 info
Change: $0 (0%) info
Market Cap: $289.45M info
TTRX
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $9.48 info
Change: $0 (0%) info
Market Cap: $289.45M info
TTRX
Nov 05, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.80
Real-time Price: $9.48 info
Change: -$0.320 (-3%) info
Market Cap: $289.45M info